| Literature DB >> 25177670 |
Alper Azak1, Bulent Huddam1, Namik Gonen2, Seref Rahmi Yilmaz3, Gulay Kocak1, Murat Duranay1.
Abstract
BACKGROUND: Chronic Heart Failure (CHF) is highly prevalent and is associated with high morbidity and mortality rates. It has been well established that excessive intake of sodium chloride (salt) induced hypertension in some populations. Although salt seems to induce cardiovascular diseases through elevation of blood pressure, it has also been indicated that salt can induce cardiovascular diseases independently from blood pressure elevation.Entities:
Keywords: Heart Failure; Inflammation; Sodium Dietary
Year: 2014 PMID: 25177670 PMCID: PMC4109042
Source DB: PubMed Journal: Int Cardiovasc Res J ISSN: 2251-9130
Demographic Characteristics and the Medications of the Patients
| Sex | Female (n = 45) | Male (n = 41) | Total (n = 86) |
|---|---|---|---|
|
| 64.51 ± 12.17 | 65.59 ± 8.02 | 64.87 ± 10.91 |
|
| 24 (53.3) | 10 (24.3) | 34 |
|
| 40 (88.9) | 29 (70.7) | 69 |
|
| 14 (31.1) | 7 (17) | 21 |
|
| 4 (8.8) | 4 (9.7) | 8 |
|
| 13(28.8) | 3 (7.3) | 16 |
|
| 14 (31.1) | 7 (17) | 21 |
|
| 20 (44.4) | 5 (12.1) | 25 |
|
| 21 (46.6) | 10 (24.3) | 31 |
|
| 9 (20) | 5 (12.1) | 14 |
|
| 15 (33.3) | 7 (17) | 22 |
|
| 7 (15.5) | 2 (4.8) | 9 |
|
| 9 (20) | 6 (14.6) | 15 |
|
| 9 (20) | 3 (7.31) | 12 |
Abbreviations: ACEI, Angiotensin converting enzyme inhibitor; ARB, Angiotensin receptor blocker; CCB, Calcium channel blocker; OAD, Oral anti diabetic; ASA, Acetyl salicylic acid
Study Groups' Characteristics Based on Their Urinary Sodium/Creatinine Ratio
| Group I (< 100 mEq/g, n=27) | Group II (100-200 mEq/g, n= 31) | Group III (>200 mEq/g, n=29) | P value | |
|---|---|---|---|---|
|
| 14 / 13 | 16 / 14 | 15 / 14 | 0.086 |
|
| 67.44 ± Kas.81 | 63.56 ± 10.9 | 65.43 ± 10.29 | 0.420 |
|
| 141.4 ± Kas.48 | 145.2 ± 15.2 | 144.13 ± 17.75 | 0.673 |
|
| 83.11 ± 10.57 | 83.84 ± 6.4 | 85.65 ± 8.7 | 0.560 |
|
| 2.3 ± 0.4 | 2.9 ± 0.5 | 3.01 ± 0.4 | 0.460 |
|
| 0.97 ± 1.03 | 1.23 ± 1.06 | 1.97 ± 0.65 b | 0.003 |
|
| 226.9 ± 579.05 | 608 ± 218.29 | 554.2 ± 112.7 | 0.497 |
|
| 76.05 ± 12.8 | 143.1 ± 28.03 | 538.05 ± 197.8 a, b | < 0.01 |
|
| 109.4 ± 77.2 | 104.8 ± 70.1 | 106.97 ± 80.54 | 0.975 |
|
| 170.5 ± 64.36 | 165.4 ± 66.9 | 152.3 ± 50.42 | 0.607 |
|
| 14.8 ± 6.12 | 15.44 ± 6.75 | 15.16 ± 6.78 | 0.941 |
|
| 397.6 ± 56.03 | 408.9 ± 69.01 | 406.48 ± 70.91 | 0.830 |
|
| 73.24 ± 47.29 | 94.9 ± 63.6 | 68.63 ± 48.2 | 0.140 |
|
| 5.46 ± 3.36 | 5.6 ± 3.05 | 5.14±3.26 | 0.780 |
|
| 22.28 ± 14.7 | 24.18 ± 17.5 | 20.3 ± 14.2 | 0.64 |
|
| 13.97 ± 1.29 | 13.85 ± 1.55 | 13.77 ± 1.32 | 0.900 |
|
| 1.09 ± 0.28 | 1.13 ± 0.35 | 0.86 ± 0.15 | 0.060 |
|
| 140.6 ± 3.05 | 140.62 ± 2.8 | 140.96 ± 2.63 | 0.870 |
|
| 4.11 ± 0.048 | 4.59 ± 0.51 | 4.55 ± 0.45 | 0.078 |
|
| 5.54 ± 1.55 | 5.8 ± 1.77 | 7.81 ± 0.86 b, c | < 0.01 |
|
| 4.2 ± 0.21 | 4.14 ± 0.33 | 4.07 ± 0.4 | 0.430 |
|
| 4 | 5 | 4 |
a, P < 0.05 Group I vs Group II
b, P < 0.05 Group I vs Group III
c, P < 0.05 Group II vs Group III
Figure 1.The Correlation between Serum HsCRP Levels and Na/Creatinin Ratio